United States - English - NLM (National Library of Medicine)

adare pharmaceuticals inc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 600 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see overdosage ). controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. potassium supplementation, when indicated in such patients, should be given as a liquid preparation. all solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholineric properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in capsule passage through the gastrointestinal tract.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 10 meq - because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - 1.for the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - 2.for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such pa

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g. digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patien

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g. digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patien

United States - English - NLM (National Library of Medicine)

pharmaceutical associates, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 3 g in 15 ml - 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwar

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags (baxter healthcare ltd - potassium chloride; glucose anhydrous; sodium chloride - infusion - 1.5mg/1ml ; 40mg/1ml ; 1.8mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 1.5mg/1ml ; 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 3mg/1ml ; 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/1litre) / glucose 5% infusion 1litre viaflo bags (baxter healthcare ltd - potassium chloride; glucose anhydrous - infusion - 1.5mg/1ml ; 50mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium pertechnetate(99mtc), quantity: 370 gbq - injection - excipient ingredients: water for injections; sodium chloride - sodium pertechnetate [99mtc] is used for scintigraphy, principally of the brain and thyroid. it can also be used to prepare various technetium-99m labelled injections for selective organ imaging especially of the liver, lung, bone and kidney.